Articles related to Hematology/Oncology

Recent studies suggest that ultra-processed foods may raise cancer risk by up to 10% for pancreatic, colorectal, and breast cancers, highlighting the importance of dietary considerations in cancer prevention.

Luspatercept demonstrates superior efficacy in achieving transfusion independence for patients with low-risk MDS compared to traditional erythropoiesis-stimulating agents.

A recent phase 3 trial comparing nivolumab plus AVD to brentuximab vedotin plus AVD in advanced-stage Hodgkin’s lymphoma demonstrated a significant improvement in 2-year progression-free survival (92% vs. 83%, respectively) with a hazard ratio for disease progression or death of 0.45 (95% CI, 0.30 to 0.65).

The study reveals that 10% of patients treated with eli-cel developed hematologic cancer, with an incidence rate of 2.1 per 100 person-years. This finding emphasizes the need for careful monitoring and risk assessment in gene therapy approaches.

Striking the balance between confidence and humility is crucial for new oncology attendings, especially when managing rare cases.

Chemotherapy-free regimens for Ph+ ALL have shown complete response rates of 94-100% with minimal toxicity, potentially eliminating the need for stem cell transplant in many patients.